4 Stocks to Buy Before the End of 2026! — Transcript
Full transcript
- 0:00Welcome back to the channel everyone.
- 0:01Today Neil and I are going to be talking
- 0:03about four stocks that we think look
- 0:05like great [music] buys before the end
- 0:07of 2026.
- 0:09Hard to believe that we're already
- 0:10getting down to the last couple months
- 0:12of [music] the year. There's a lot of
- 0:13businesses that I think we both have on
- 0:15our watch lists on our buy lists and
- 0:17we're going to be talking about some
- 0:18names across a few different industries
- 0:20right now. [music] A couple of these
- 0:21might be a little bit more unexpected.
- 0:23Excited to dive right in.
- 0:31Neil, good to see you today.
- 0:34>> Good to see you as well. And it is quite
- 0:36uh quite crazy that we are almost almost
- 0:40in 2027.
- 0:42So yeah, whoever is still uh wanted to
- 0:44sign up to the gym, something that you
- 0:47promised yourself in January may maybe
- 0:49January 2027,
- 0:51>> you have another chance. It's coming
- 0:52right around the corner.
- 0:54Uh but I'll I'll uh start off with my
- 0:58first one. My first one is a name that
- 1:00did report on Monday, November 9th,
- 1:04their quarterly figures, and that's
- 1:05Rocket Lab. Now, Rocket Lab is a company
- 1:08where I don't think looking at it from a
- 1:12purely valuation standpoint anybody's
- 1:14going to buy it because it's cheap. It's
- 1:16just less expensive. And it's also about
- 1:20what the company could look like 5 10
- 1:22years down the line. Now they reported
- 1:25revenue up 73% year-over-year, 14.4% up
- 1:30sequentially.
- 1:32They of course they launch rockets. They
- 1:34have a launch business and they also
- 1:36have a a space systems business. That
- 1:39one was up 13% uh sequentially which is
- 1:42and it was around I think 80% of the
- 1:44overall revenue. All of that is is good
- 1:47and fine, but the real story is again
- 1:49about what happens in the future. Rocket
- 1:53Lab stock, I think we reached a peak of
- 1:55$150 this year. It's now trading in the
- 1:57low $50. So quite quite a rocket crash
- 2:02uh since the uh since the highs. But the
- 2:06reason why this has happened is not
- 2:08because of a rocket exploded. No, it's
- 2:10because one was super expensive,
- 2:12overvalued, and two, their next big
- 2:16rocket, which is Neutron, was supposed
- 2:18to have its first flight, let's say, at
- 2:22the end of this year, although I don't
- 2:24think that was realistic, and that was
- 2:26delayed yet again. It's been quite a
- 2:30couple of quarters, maybe a year or two
- 2:32of delays. The thing here is nice for
- 2:352027. We still don't know when in 2027
- 2:38where it's going to be probably not Q1
- 2:40but maybe Q2 maybe midway 2027. And the
- 2:44reason why Neutron is so important is
- 2:46because well whenever you launch a a
- 2:49Neutron rocket it costs way more than
- 2:51Electron. Electron is their really
- 2:53really small rocket and by the way
- 2:55they're soon going to be launching their
- 2:57100th uh rocket which I think is the
- 3:00fastest company to to achieve that. But
- 3:04Neutron is very important to the
- 3:06long-term story of this business.
- 3:08Reusable rockets is very important.
- 3:10Capacity goes up quite a lot. More
- 3:12satellites go to space. The contracts
- 3:14get bigger and bigger. The launch
- 3:16contracts get of course more lucrative
- 3:17as well. This quarter they did tell us
- 3:21despite despite not launching one
- 3:23neutron rocket and despite many many
- 3:26delays we've seen total backlog
- 3:28increased by 52% sequentially not
- 3:31year-over-year sequentially to now $3.57
- 3:34billion. They've signed 54 launches
- 3:38overall worth more than a billion dollar
- 3:41total. They've sold eight new Neutron
- 3:44launches for about $515 million, which
- 3:48they also told us that some of them have
- 3:51been priced at a higher um sale price of
- 3:54around $70 million, which I think the
- 3:57base price was 15 uh $55 million. So,
- 4:01even with all the delays, even without
- 4:03launching one Neutron rocket, they
- 4:05managed to just increase the price to 70
- 4:09million. and and that's the that's the
- 4:11story here. The backlog is not all an
- 4:13option. It's sort of real contracts,
- 4:17but they need to deliver. There's a lot
- 4:19of cost going into developing a rocket
- 4:22such as Neutron. So hopefully hopefully
- 4:25a year from now we will have already had
- 4:28a launch of Neutron. Hopefully that
- 4:30backlog also keeps on increasing. We
- 4:32will also have the complete acquisition
- 4:35of Idium which would make the whole
- 4:37rocket lab business more profitable.
- 4:39Redium is already generating free cash
- 4:41flow. So, it helps a business that is
- 4:43burning cash because it is developing
- 4:45rockets. And who knows, maybe the first
- 4:47Neutron Rocket launch is going to be
- 4:49successful. Maybe not. But it's
- 4:51definitely a business that still needs a
- 4:53lot of cash. I do think that the big big
- 4:55pullback that we've experienced in the
- 4:58recent months does give me a big a
- 5:01better opportunity to accumulate more
- 5:03shares.
- 5:05>> Yeah, I think that's right. a
- 5:07fascinating business to watch and um
- 5:09incredibly wellrun as well by Sir Peter
- 5:12Beck. With that, I want to talk about
- 5:13the next stock for today. Switching
- 5:16gears to a completely different
- 5:17industry. Got to talk about healthcare.
- 5:19I'm going to talk about Crystal Biotech,
- 5:21ticker KR YS. So, Crystal Biotech, if
- 5:25you're not familiar, a little bit
- 5:26unusual in the world of growth biotech
- 5:28names. This is a commercial stage
- 5:30company. They already have an approved
- 5:32very profitable product. So this is not
- 5:34a a bet on a future clinical trial
- 5:36outcome. Uh Crystal Biotech's flagship
- 5:39drug is a therapy called VIVEC. It is
- 5:42the world's first topically applied
- 5:44atome gene therapy and it treats a
- 5:47condition known as uh distrophic
- 5:50epidermalisa or deeb. This is a very
- 5:52severe painful genetic skin disease. It
- 5:55causes horrible blistering and chronic
- 5:57wounds uh because of faulty collagen
- 5:59genes. And crystal biotech drug uses a
- 6:03modified a harmless version of the
- 6:05herpes virus to deliver a working copy
- 6:08of that gene right into a patient's own
- 6:11skin cells. So it's actually applied as
- 6:13a simple gel that a patient could use
- 6:16repeatedly at home. This isn't through a
- 6:18single, you know, one-time infusion. And
- 6:21that redossible delivery platform isn't
- 6:23just useful for this one rare disease.
- 6:25It's the foundation that Crystal Biotech
- 6:27is now extending to new programs where
- 6:30they are targeting other rare conditions
- 6:32of the lungs, the eyes, other rare skin
- 6:35disorders. So, it's really interesting,
- 6:38you know, how they built their platform
- 6:39around uh the herpes simplex virus. This
- 6:43is a a virus that has evolved over a
- 6:45long time to be good at two things,
- 6:46which is infecting skin cells and hiding
- 6:49from the body's immune system well
- 6:51enough to stay in a person for life
- 6:54without being permanently cleared. And
- 6:56so Crystal Biotech platform actually
- 6:58capitalizes on these two natural
- 7:00properties, but for a therapeutic
- 7:02purpose. Um, and that means that they
- 7:05are able to replace uh corrective copy
- 7:08of whatever gene a patient is missing,
- 7:11keep the virus's natural skill at
- 7:13slipping into skin cells without
- 7:14triggering any kind of a negative immune
- 7:16response within the patient. Now, just
- 7:20to put some numbers to how the company
- 7:22has been performing, they recently
- 7:24released their Q3 results in early
- 7:26November. Global revenue was $127
- 7:30million. That was up 30% year-over-year.
- 7:32Their cumulative revenue since they
- 7:34launched Fijc is now at just over a
- 7:37billion dollars. Uh their gross margin
- 7:39is at 94%. They ended the quarter with
- 7:42about 1.2 billion in cash and
- 7:45investments.
- 7:47Now the stock has been under a little
- 7:48bit of pressure uh since they reported
- 7:50earnings. It actually dropped around 10%
- 7:53or more on the day of their earnings
- 7:55report. And that was primarily because
- 7:57management disclosed that they have a
- 7:59few a few key clinical data readouts for
- 8:02two of their key pipeline candidates
- 8:04have been pushed into 2027 rather than
- 8:07being released before the end of the
- 8:10year. So they have a uh therapeutic
- 8:13candidate that targets a rare eye
- 8:15condition. They are going to be
- 8:17reporting topline results from their
- 8:20ongoing clinical trials early next year.
- 8:22They have a cystic fibrosis therapy that
- 8:25has now uh been delayed the results
- 8:28until the first half of 2027. Says
- 8:31nothing about uh you know anything with
- 8:33regards to the business to be concerned
- 8:34about but just something to be aware of.
- 8:37You know Crystal Biotech has continued
- 8:38to expand internationally. They have uh
- 8:41of course expanded and launched within
- 8:43the US but they are done with pricing
- 8:45and reimbursement negotiations in
- 8:47markets like Germany and Italy. So,
- 8:49they're going to be launching uh within
- 8:51some of these markets as early as the
- 8:53beginning of 2027. Uh they're already
- 8:56benefiting from earlier European
- 8:58launches as well as expansion in Japan.
- 9:02And I'll also note that Crystal Biotech
- 9:04Board has authorized a $400 million
- 9:06share buyback program that's going to be
- 9:08executed over the next couple years. So,
- 9:11fascinating business, very much in the
- 9:13early stages of its growth. It has its
- 9:15one very profitable key flagship
- 9:17product, but they are rapidly expanding
- 9:19into other rare disease areas. It's a
- 9:22profitable business. It's a high margin
- 9:23one. Might be one to at least put on
- 9:26your watch list, if not your buy list,
- 9:28if you're interested in putting cash to
- 9:30work in biotech stocks.
- 9:33>> Very interesting name. I mean, the
- 9:34biotech
- 9:36segment of the market is one where it's
- 9:39either you're going to be very very
- 9:40successful or or it's a name where you
- 9:43probably won't hear about it a couple of
- 9:46years a couple of years down the line,
- 9:47but from what I I've just heard and and
- 9:50seen seems like a a pretty good company
- 9:52has also performed quite well uh this
- 9:54year and and over the past uh 12 months.
- 9:57So, pretty pretty good. Um my my next
- 10:00one is is a company that well how should
- 10:04I say over the last couple of years has
- 10:06completely changed changed the game in
- 10:09the in the stock market over the past
- 10:11couple of days has definitely changed
- 10:14something in uh in the news market and
- 10:17that's Nvidia. Now Nvidia we all know it
- 10:21I mean now it's not a $5 trillion
- 10:23company anymore. it has lost a little
- 10:25bit of it of its market cap over the
- 10:27past couple of days and weeks.
- 10:31Some of the reasons we know what's going
- 10:32on in the headlines right now with uh
- 10:35with the CEO, but I do want to talk
- 10:36about the business itself because the
- 10:39business is still a tremendous business.
- 10:42Yes, it's true that Jensen being the
- 10:45CEO, Jensen being Nvidia, Nvidia being
- 10:47Jensen, if let's say he were to step
- 10:50down, that could cause some pressure on
- 10:52the stock, would it would it be a thesis
- 10:56changer? I I doubt it because I do think
- 10:59that Nvidia has become a such a big
- 11:02company that that could be run by
- 11:05someone else. Of course, ideally Jensen
- 11:08does stay the company, but purely
- 11:09looking at the business today. I don't
- 11:12think that anything will change anytime
- 11:14soon. I still think they'll grow at
- 11:16least 70% uh next year. I still think
- 11:19that Google, Amazon, OpenAI, all of
- 11:22these uh companies are still going to
- 11:24buy Nvidia GPUs for for the foreseeable
- 11:27future. and and that represents right
- 11:30now a a a in my opinion a buying
- 11:33opportunity because valuation wise I
- 11:35think we're at 17 times forward earnings
- 11:38or or close to it of course generating
- 11:41an insane amount of free cash flow over
- 11:43the next couple of years will be
- 11:44generating well over half a trillion
- 11:46dollars in in free cash flow which is
- 11:49which is mindboggling so despite all of
- 11:52the headlines more recently whether it's
- 11:55around uh data center buildout AI high
- 11:58investments or now the new headlines
- 12:00that have popped up uh the the
- 12:02controversy around around the the CEO. I
- 12:06do think that the pressure of the stock
- 12:08does present long-term investors a a
- 12:11nice opportunity where the riskreward
- 12:13definitely favors the rewards or at
- 12:15least for me again because I do think
- 12:18that the AI buildout does continue. We
- 12:21spoke about cororewe in a in a previous
- 12:24video. Of course, Nvidia is an investor
- 12:26in Cororeef. Corre does buy a lot of
- 12:28Nvidia chips. Yes, we could say that
- 12:30Nvidia also backs Cororey, although two
- 12:33different terms maybe, but uh if
- 12:35Cororeef doesn't manage to to to sell X
- 12:38amount of chips, Nvidia will come in and
- 12:41and back them for at least I think $6
- 12:43billion or so. Some might like these
- 12:45deals, some might not. That's completely
- 12:47fine. But
- 12:50Nvidia is is in a very good spot at the
- 12:53moment in this whole AI buildout. Stock
- 12:56is cheap. Business is growing. I mean
- 12:58the size of the business. This is now a
- 13:00four plus trillion dollar company
- 13:02generating tens of billions, hundreds of
- 13:04billions of dollars in revenue while
- 13:06still growing at least 70%. That's for
- 13:09next year. This year is going to be
- 13:10closer to 90% or so. very very
- 13:13profitable despite despite some of their
- 13:15biggest customers also becoming let's
- 13:18say rivals
- 13:20all designing their own custom silicon
- 13:23or the old custom chips working with
- 13:25Broadcom working with Marvel so yes
- 13:28there is a lot of com or AMD as well uh
- 13:30we've seen the Google TPU's uh
- 13:32announcement with uh with AMD I think on
- 13:34Monday so competition is increasing I do
- 13:38also think the momentum the market is
- 13:40just growing so much Nvidia's position
- 13:42very well very profitable company. Yes,
- 13:46unfortunately we do have some negative
- 13:48headlines affecting the stock. Could it
- 13:51affect the business? There's definitely
- 13:53a chance that it could affect the
- 13:55business where XYZ were to happen over
- 13:58the next couple of weeks. So, we'll see.
- 14:01But purely looking at valuation and
- 14:04business performance, I'd had to put uh
- 14:07this name right now on the list,
- 14:09especially since we are at the end of
- 14:112026 and I didn't think we would see an
- 14:12Nvidia trading at 17 times forward
- 14:15earnings by the end of this year.
- 14:18Yeah, I mean certainly the financial
- 14:20foundation of Nvidia, the business is
- 14:24you know running like a welloiled
- 14:25machine and the tailwinds that are
- 14:27driving the business forward just
- 14:29broadly those secular tailwinds are not
- 14:31going to go anywhere regardless of what
- 14:33happens with you know the story that
- 14:36we're seeing around the CEO in the
- 14:38coming weeks and months. Who knows if we
- 14:40will see a leadership change or not, but
- 14:43uh and that may in fact be you know
- 14:45necessary and that may shake the stock
- 14:46up and you know we will see. We don't
- 14:48want to speculate about what's going to
- 14:50happen. Um but certainly the core
- 14:52underlying business uh is one that I
- 14:55think remains deeply tethered to the AI
- 14:58buildout that's arguably one of the most
- 14:59recognizable names in the space. Um and
- 15:02probably has one of the strongest
- 15:03financial foundations of any of the AI
- 15:05companies uh that we talk about. Um, for
- 15:08the final stock in today's video, I'm
- 15:10going to talk about another healthcare
- 15:11name. Another one that's probably a bit
- 15:13less known. Trying to shake it up a
- 15:15little bit. You know, we see in the
- 15:16comments sometimes that you guys uh
- 15:18mention that we only talk about tech
- 15:19stocks. So, I'm trying to shake things
- 15:21up a bit. We'll see. Uh, so Billionto
- 15:23One, uh, ticker B LLN. If you're not
- 15:26familiar with Billion to One, this is
- 15:28certainly not a household name. They are
- 15:30a molecular diagnostics company. So
- 15:32their platform is built around a kind of
- 15:34proprietary technology that it calls
- 15:37quantitating quantitative counting
- 15:39templates or QCT. This is essentially a
- 15:42platform that can detect and measure uh
- 15:44genetic material with a level of
- 15:46sensitivity that the legacy diagnostic
- 15:49companies generally can't match. And
- 15:51Billionto one applies that technology
- 15:53across a couple different product lines.
- 15:56The first and currently its flagship
- 15:58business is prenatal testing. uh they
- 16:01have the first and only non-invasive
- 16:03prenatal tests uh for red blood cell and
- 16:06platelet fetal antigens in the US. The
- 16:08second is their oncology business and
- 16:10they are currently building out a an
- 16:12entire family of liquid biopsy tests
- 16:15that can detect and monitor cancer from
- 16:17a simple blood draw rather than
- 16:19requiring an invasive tissue biopsy. And
- 16:21the oncology business is the one that
- 16:23I'm most excited about that I think will
- 16:25be most important to the business and
- 16:27its growth story moving forward.
- 16:30So one of the things that's interesting
- 16:32uh talking about the the platform
- 16:34technology that billion to one runs on
- 16:38um just to explain why it's a bit more
- 16:41differentiated. So when you draw blood
- 16:43from a pregnant woman there's a t tiny
- 16:45amount of fetal DNA that's floating
- 16:47freely in her bloodstream and that's
- 16:49mixed in with a much larger amount of
- 16:51her DNA. So pulling a faint specific
- 16:53fetal signal out of that much larger
- 16:55background of DNA is sort of the central
- 16:58challenge of non-invasive prenatal
- 17:00testing. That same kind of basic core
- 17:03challenge also shows up in cancer
- 17:05testing. So for example, after a tumor
- 17:07is removed, there might only be a
- 17:09handful of cancer DNA fragments floating
- 17:11among millions of healthy ones. And so
- 17:13finding those few fragments is what
- 17:15minimal residual disease testing is
- 17:18actually trying to do. billion to one's
- 17:20platform attaches a unique tag to each
- 17:25individual DNA molecule. So they can
- 17:27actually count those molecules rather
- 17:29than estimate their proportion. You
- 17:31could sort of think of it of as the
- 17:33difference between weighing a mixed bag
- 17:35of coins to estimate how many quarters
- 17:36are in it versus tagging and counting
- 17:38each coin at a time. And that precision,
- 17:41that single molecule level precision is
- 17:43what allows billion to one to offer
- 17:46these very accurate diagnostic tests
- 17:49that so far some of the more established
- 17:50competitors have not. Um, and this is
- 17:53showing up in the numbers as well. So
- 17:55they reported also about a week ago
- 17:57their third quarter results. Total
- 17:59revenue
- 18:00uh beat uh consensus estimates was up
- 18:04about 50% year-over-year. saluted
- 18:06earnings per share was more than double
- 18:08what Wall Street was expecting. Their
- 18:10prenatal revenue was up 41%
- 18:12year-over-year. Their oncology revenue,
- 18:14which is still a smaller, but the
- 18:15fastest growing part of the business,
- 18:17was up 96% year-over-year, is now
- 18:20running at an annualized rate of about
- 18:2168 million. They generated about $9
- 18:24million in free cash flow in the
- 18:26quarter. It was their fifth consecutive
- 18:28quarter of positive GAP operating
- 18:31income. They have about 562 million in
- 18:34cash and cash equivalents on their
- 18:35balance sheet. One of the biggest things
- 18:37to watch as it pertains to the oncology
- 18:39business, they have a new test that they
- 18:42are launching in mid December. This is a
- 18:44a test for minimal residual disease.
- 18:46Basically, it's designed to detect the
- 18:48microscopic traces of cancer left behind
- 18:50after a patient's tumor has already been
- 18:53surgically removed. It's a blood only
- 18:55test. It is available for all solid
- 18:57tumors. Was day one. um and they're
- 18:59going to be uh launching this again here
- 19:02in the next few weeks. And so this is uh
- 19:05key as they are growing out their cohort
- 19:07of oncology tests. It it's a fascinating
- 19:10business. It's a profitable one. It's
- 19:13one that's continuing to see really
- 19:14solid growth across both their prenatal
- 19:17natal testing and oncology businesses.
- 19:20Uh but to me the fact that they are
- 19:22launching these really differentiated
- 19:24cancer monitoring products into uh a
- 19:27vast addressable market management uh
- 19:30estimates that that market is worth
- 19:31about $30 billion on top of this already
- 19:34validated technology platform. I think
- 19:37there's a long way for billion to want u
- 19:40to run and I think this is certainly a
- 19:41business to at least put on your watch
- 19:43list before the end of 2026.
- 19:46It's certainly a very cool name.
- 19:49>> Billion to one. It's very catchy.
- 19:52>> Yeah.
- 19:53>> Okay, everyone. That's [music] four
- 19:54stocks that Neil and I would consider
- 19:56buying before the end of 2026. For Neil,
- 19:59we [music] had Rocket Lab and Nvidia. I
- 20:01talked about two healthcare names,
- 20:02Crystal Biotech and Billion. [music] Let
- 20:05us know your thoughts in the comments.
- 20:06What stocks are on your buy lists before
- 20:09the end of the year? Let us know. Hit
- 20:11the like and subscribe buttons and we
- 20:13will see you in the next video.
About this transcript
This page contains the full transcript of 4 Stocks to Buy Before the End of 2026! by The Motley Fool, generated from the public captions YouTube serves with the video. The transcript has 3,408 words across 509 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.